BELLICUM PHARMACEUTICALS, INC: Nasdaq/NYSE listing notice — Bellicum receives dual Nasdaq deficiency notices for equity and bid price

BELLICUM PHARMACEUTICALS, INC

Stockholders' equity below Nasdaq Capital Market requirement of $2.5M per April 6 notice; 45 days to submit compliance plan.
Bid price closed below $1.00 for 30 consecutive days as of April 10; 180 days to regain compliance.
If bid price falls to $0.10 or less for 10 straight days, immediate delisting may occur.
Company evaluating options but cannot assure compliance will be achieved.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 10, 2023 Nasdaq Notice On April 10, 2023, the Company received notice (the “Bid Price Notice”) from Nasdaq advising the Company that for 30 consecutive trading days preceding the date of the Bid Price Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company has 180 calendar days from the date of the Bid Price Notice to regain compliance with the Minimum Bid Price Requirement. If at any time during

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 6, 2023 Nasdaq Notice On April 6, 2023, Bellicum Pharmaceuticals, Inc. (the “Company”) received notice (the “Stockholder’s Equity Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1). The Company has 45 calendar days from the date of the Stockholders’ Equity Notice to submit to Nasdaq a plan to regain compliance. The Company is currently eval

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001628280-23-011198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.